Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
Sponsor: Universität Münster
Summary
The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.
Official title: A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1022
Start Date
2025-03-31
Completion Date
2027-04
Last Updated
2025-07-18
Healthy Volunteers
No
Conditions
Interventions
Angiotensin II
Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
Noradrenalin
Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
Locations (4)
Deutsches Herzzentrum der Charité
Berlin, Germany
University Hospital Bonn
Bonn, Germany
University Medical Center Mainz
Mainz, Germany
University Hospital Münster
Münster, Germany